Clinical trials: Skin Lesion
Skin Diseases
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
5 Day study to assess how quickly a topical acne product begins to work.
- Trial name
- NCT02052752
- Testing
- 3% Benzoyl Peroxide, Neutrogena Rapid Clear®
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Vitiligo
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
- Trial name
- NCT04547998
- Testing
- Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Avita Medical
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.
Contact Dermatitis
Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
The purpose of this study is to evaluate the diagnostic performance and safety of ascending doses of mercury, aluminum and palladium metal allergens proposed for inclusion in a metal allergen panel.
- Trial name
- NCT02028208
- Testing
- Ammoniated mercury, Aluminum chloride and aluminum lactate, Sodium tetrachloropalladate
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- Allerderm
Dermatitis, Allergy
Human Repeated Insult Patch Test
Repeated insult patch test on healthy males and females to determine potential contact irritation or contact allergy in the skin
- Conditions
- Dermatitis, Allergy, Contact Allergy
- Trial name
- NCT03474874
- Testing
- NeoMatriX Collagen Dressing
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- NeXtGen Biologics, Inc.
Psoriatic Arthritis
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.
- Trial name
- PALACE 3 (NCT01212770)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 505 people
- Sponsor
- Amgen
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Skin Infections, Bacterial
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions…
- Trial name
- NCT00684177
- Testing
- Retapamulin Ointment, 1%
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 508 people
- Sponsor
- GlaxoSmithKline
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratosis
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
- Trial name
- NCT02632110
- Testing
- ALA, Topical Solution Vehicle, IBL 10 mW
- Where
- 8 sites in United States
- Volunteers
- 137 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Advanced Melanoma
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
ATLAS-IT-05 was an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who had either exhausted treatment options or were…
- Trial name
- ATLAS-IT-05 (NCT04796194)
- Testing
- LTX-315 in combination with pembrolizumab
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 23 people
- Sponsor
- Lytix Biopharma AS
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Skin Texture, Pigmented Lesions
Nonablative Fractional Diode Laser for Treatment of Skin Resurfacing and Pigmented Lesions
This study is intended to evaluate the efficacy and safety of a new diode fractional laser for skin resurfacing and treatment of pigmented lesions.
- Trial name
- NCT04203745
- Testing
- Nonablative Fractional Diode Laser
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Hypersensitivity
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions.
- Trial name
- NCT04531540
- Testing
- Butenafine HCl 1% (BAY1896425)
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Bayer
Cumulative Irritation
14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
The objective of this study is to determine the ability of the study material to cause irritation to the skin of humans under controlled patch test conditions.
- Trial name
- NCT02309294
- Testing
- Novel lubricant Miami w/ fragrance, Novel lubricant Miami no fragrance, KY Liquid lubricant
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Secondarily Infected Traumatic Lesions (SITL), Impetigo
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic…
- Trial name
- NCT00758862
- Testing
- 2% TD1414 Cream
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- LEO Pharma
Pigmented Skin Lesion
Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides…
- Trial name
- NCT04202419
- Testing
- FRAX 1940 nm laser
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Rheumatoid Arthritis
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
This is a phase IV, open-label and single-arm study of patients with non-malignant pain due to osteoarthritis, rheumatoid arthritis, low back pain and joint/muscle pain, who were not responding to non-opioid analgesics.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT02519387
- Testing
- Buprenorphine Transdermal Patch
- Where
- 3 sites in Malaysia
- Volunteers
- 78 people
- Sponsor
- Mundipharma Pharmaceuticals Sdn. Bhd.